| NUKLEONIKA 2005, 50(3):91-96
DEVELOPMENT OF 111In-DTPA-HUMAN POLYCLONAL ANTIBODY COMPLEX FOR LONG-TERM INFLAMMATION/INFECTION DETECTIONAmir R. Jalilian1, Pejman Rowshanfarzad1, Kamaleddin Shafaii2, Mohsen Kamali-Dehghan1, Jamshid Moafian1, Mahdi Akhlaghi1, Mohammad Babaii3, Saeed Rajabifar1, Mohammad Mirzaii1 1 Cyclotron and Nuclear Medicine Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran, P. O. Box 31485-498 2 Nuclear Agriculture Department, Nuclear Research Center for Agriculture and Medicine (NRCAM), Atomic Energy Organization of Iran (AEOI), Karaj, Iran 3 Nuclear Research Center, Atomic Energy Organization of Iran (AEOI), North-Kargar Str., Tehran, Iran Human polyclonal antibody (HIgG) was successively labeled with 111In-indium chloride after residulation with freshly prepared cyclic DTPA-dianhydride. The best results of the conjugation were obtained by the addition of solid DTPA-dianhydride (0.1-0.3 mg) to 100 ml of the HIgG solution (0.2-0.4 mg/ml) at pH = 6 in phosphate buffer media at 25°C with continuous stirring for 30 min. Radio-thin-layer chromatography showed an overall radiochemical yield of 96-99% at optimized conditions (specific activity = 300-500 MBq/mg, radiochemical purity >98%). The final isotonic 111In-DTPA-HIgG complex was checked by radio-TLC to ensure the formation of only one species followed by filtration through a 0.22 m filter. Preliminary long-term in vivo studies in turpentine-oil induced inflammation in rat model was performed to determine late complex distribution of the radioimmunoconjugate. The target/skin and target/blood ratios were 27 and 51 after 24 h, and 23 and 51 after 110 h, showing a high selectivity of the radiopharmaceutical for inflammatory lesions. Close X |